|
|
Vol. 15.11 – 18 June, 2026
|
|
|
|
|
|
|
|
|
Scientists addressed the origins of the signature, first determining that basal, club, neuroendocrine, and AT2 epithelial lineages are competent to form EGFR-driven lung adenocarcinoma, with conserved keratin 8+ alveolar intermediate cell-like states observed within the alveolar niche. [Cell]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers identified p16 as a mechanistically defined regulator of fibrosis progression and suggested that modulating this axis may offer new opportunities for therapeutic intervention in idiopathic pulmonary fibrosis.
[Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
Investigators identified RING-box protein 1 (RBX1) as a critical regulator of airway epithelial injury, whose expression is markedly elevated in asthma.
[Bioorganic Chemistry]
|
|
|
|
|
|
|
|
Through an integrated screening combining bioinformatics, transcriptomics, and clinical prognostic analysis, the authors identified E3 ubiquitin ligase speckle-type POZ protein (SPOP) as a key tumor suppressor in lung adenocarcinoma.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
Using multiple experimental approaches, including the Cell Counting Kit-8 assay, colony formation assay, flow cytometry, RNA sequencing, and Western blot analysis, investigators systematically evaluated the in vitro effects of Carnosol on lung cells
[Biochemical Pharmacology]
|
|
|
|
|
|
Researchers identified the pyrroline-5-carboxylate reductase 1 (PYCR1)/OPLAH axis as a key driver of LUAD progression via p53 signaling, revealing a promising therapeutic target. [Clinical and Experimental Medicine]
|
|
|
|
|
|
|
|
Scientists highlight the effectiveness of in-silico methods in identifying promising phytochemicals, such as quercetin and curcumin, that target key molecular pathways in lung cancer. [Discover Oncology]
|
|
|
|
|
|
|
|
Two new grants from the Cancer Prevention and Research Institute of Texas (CPRIT) bring the total of active CPRIT grants at the University of Houston (UH) to $11.1 million, and both are meant to develop new strategies to fight lung cancer. [University of Houston]
|
|
|
|
|
|
|
|
July 12-16, 2026 Washington, DC, United States
|
|
|
|
|
|
|
|
|
|
|
Örebro University – Örebro, Sweden
|
|
|
|
|
|
|
University of Zurich – Zurich, Switzerland
|
|
|
|
|
|
|
The Icahn School of Medicine at Mount Sinai – New York City, New York, United States
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
Indiana University – Indianapolis, Indiana, United States
|
|
|
|
|
|